Abstract：Objective To explore the application value of Cabergoline in the treatment of abnormal menstruation and galactorrhea in women with hyperprolactinemia. Methods Patients with hyperprolactinemia treated from June 2014 to June 2017 in the First Hospital of Shijiazhuang City were selected. They were divided into two groups according to the random number table. The observation group (n = 45) was treated with Cabergoline, while the control group (n = 45) was treated with Bromocriptine. Before and after treatment, the changes of the serum prolactin value, the clinical symptom effect, the incidence of drug adverse reaction and the drug resistance of the two groups were recorded. Results The serum prolactin values of observation group at 2 and 3 months after treatment were lower than those of control group (P < 0.05). The effective rate of abnormal menstruation in observation group was higher than that of control group (P < 0.05). There was no statistically significant difference in treatment efficiency between the two groups for galactorrhea, visual impairment, headache and other symptoms (P > 0.05). The incidence of adverse reaction such as nausea, vomiting, hypotension, and mental symptoms in observation group were lower than those in control group (P < 0.05). There was no statistically significant difference in drug resistance rate between two groups (P > 0.05). Conclusion Compared with the Bromocriptine, Cabergoline has better effect on reducing prolactin value, improvement of abnormal menstruation and lower incidence of drug adverse reactions in women with hyperprolactinemia.
2018, Vol. 15 
京公网安备 11010502046598号